Kyverna Therapeutics
Clinical-stage biopharmaceutical company developing novel cell therapies for patients with autoimmune diseases using CAR-T technology originally developed for cancer treatment.
Website
https://www.kyverna.comLocation
Emeryville, California, USA
Founded
2018
Categories
biotech, cell-therapy, car-t, autoimmune-disease, immunology
Notes
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing CAR-T cell therapies for autoimmune diseases. The company is pioneering the application of chimeric antigen receptor (CAR) T-cell technology, originally developed for cancer, to treat severe autoimmune conditions by targeting and eliminating autoreactive B cells.
The company completed its IPO in February 2024 on NASDAQ under the ticker KYTX. Kyverna's lead product candidate, KYV-101, targets CD19 and is being developed for multiple autoimmune indications.
Team
- Peter Maag, Ph.D. - Chief Executive Officer (former CEO of CareDx)
- LinkedIn: linkedin.com/in/petermaag
- James Chung, M.D. - Chief Medical Officer
- Dominic Borie, M.D., Ph.D. - Chief Scientific Officer & Co-Founder
- Shannon Aukerman - Chief Financial Officer
Additional Research Findings
- Founded in 2018, co-founded by Dominic Borie, M.D., Ph.D.
- IPO in February 2024 on NASDAQ (KYTX)
- Headquarters in Emeryville, California
- Lead candidate KYV-101 is an autologous CD19-targeting CAR-T therapy
- Targeting autoimmune diseases including lupus nephritis, myositis, and systemic sclerosis
- Raised $100M+ in Series C funding prior to IPO
- Backed by investors including Westlake Village BioPartners, 5AM Ventures, and GV